Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults ...
Many symptoms of MS are visible to the outside world, such as movement or speech problems, but there are also invisible symptoms (unseen by others) that significantly impact the lives of those living ...
De nombreux symptômes de la sclérose en plaques (SEP) sont visibles, comme les problèmes de mouvement ou de parole, mais il existe aussi des symptômes invisibles qui impactent considérablement la vie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback